ESMO 2022 NSCLC Highlights-ESMO 2022 Meeting Highlights Webinar

Video Transcription

Video Summary

In this ISLC ESMO 2022 NSCLC Highlight Webinar, several studies were discussed that have an impact on the management of patients with non-small cell lung cancer (NSCLC). The Apple trial focused on EGFR mutant NSCLC patients and explored the feasibility of performing longitudinal liquid biopsies to detect the T790M mutation and guide treatment decisions. The trial showed that liquid biopsies can be successful in genomic profiling and selecting treatment based on the results. The CODBREAK-200 trial looked at patients with KRAS-G12C mutations and showed that Soto-RASIP improved progression-free survival compared to docetaxel. The study also highlighted the importance of considering combination strategies with Soto-RASIP, such as combining it with platinum-doublet chemotherapy. The webinar also discussed immune checkpoint inhibitors in the first-line setting for non-oncogene addicted tumors. The Poseidon trial demonstrated the benefits of combining chemotherapy with anti-CTLA-4 and anti-PD-L1 agents, while the Emperlung-1 trial showed the efficacy of semi-plumab in patients with high PD-L1 expression. The KNH9-091-PERLS study investigated adjuvant immunotherapy with pembrolizumab and adjuvant chemoradiation. The study showed positive results in terms of disease-free survival, but the benefits varied depending on PD-L1 expression. Other studies, like the ADORA trial, focused on adjuvant osmiran-tinib in resected stage 1B3 to 2 or 3A NSCLC with EGFR mutations, showing a significant improvement in disease-free survival with osmiran-tinib. Overall, the webinar highlighted the importance of selecting the right treatment strategies based on patient and tumor characteristics and the potential for combining different treatment modalities to improve outcomes.

Keywords

liquid biopsies

Soto-RASIP

KRAS-G12C mutations

combination strategies

immune checkpoint inhibitors

semi-plumab

PD-L1 expression

adjuvant immunotherapy

osmiran-tinib

disease-free survival